Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.

Amylyx Pharmaceuticals announced an infusion of $135 million in Series C funds to support the late-stage development of the Boston-based company’s lead candidate, AMX0035, for amyotrophic lateral sclerosis (ALS). 

The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers. 

Hong Kong-based Insilico Medicine closed on a Series C financing round worth $255 million.

Based in South San Francisco, Lyell Pharmaceuticals filed for an initial public offering (IPO) with plans to raise $150 million. The preclinical biotech raked in $493 million in a Series C round on March 12, 2020. 

Alloy Therapeutics and Pyxis Oncology announced the formation of their joint venture, Kyma Therapeutics, which will develop immune-modulating antibodies in an attempt to tackle cancer and autoimmune diseases.

Three biopharma companies became publicly traded companies and made their debut on the Nasdaq this week.

Clover Biopharmaceuticals raised a $230 million series C round co-led by GL Ventures and Temasek, which will push the Chinese fusion protein company’s Covid-19 vaccine into Phase II/III testing and production planning.

Affinivax Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, announced the closing of a $226 million Series C financing.

XtalPi Inc., an AI-based pharmaceutical technology company with an AI-powered platform that twins with existing R&D pipelines, raised an additional $318.8 million through a Series C financing round to bring drug development into the future.